Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study

Table 4 The impact on clinical outcomes of switching to risperidone, compared with switching to olanzapine

	Estimate	95% confidence interval	P-values
Cox regression	Hazard ratio^a
Medication switch	1.44	0.97, 2.12	0.070
Relapse	3.43	1.43, 8.26	0.006
Linear regression	Coefficient^b
Change in CGI-SCH overall score before and after switching	0.29	0.06, 0.52	0.013
Change in weight (kg) before and after switching	0.22	−1.37, 1.81	0.785
Logistic regression	Odds ratio^c
EPS	4.02	1.49, 10.89	0.006
Loss of Libido	1.77	0.93, 3.37	0.083
Impotence/sexual dysfunction	1.93	0.95, 3.94	0.070
Amenorrhea/galactorrhea	8.99	2.30, 35.13	0.002

^aA hazard ratio of more than 1 indicates an increased risk of medication switch or relapse, compared with patients switched to olanzapine.
^bLinear regression modeled a change in CGI-SCH overall score (or weight) before and after switching. Coefficients indicate an estimated difference in the change, compared with patients switched to olanzapine.
^cAn odds ratio of more than 1 indicates an increased likelihood of having tolerability outcomes compared with patients switched to olanzapine.

ISSN: 1471-244X